|
Treatment
|
Liver function biomarkers
|
Kidney function biomarkers
|
|---|
|
AST (Unit/L)
|
ALT (Unit/L)
|
Bilirubin (mg/dl)
|
BUN (mg/dl)
|
Creatinine (mg/dl)
|
|---|
|
PBS
|
168 ± 63.3
|
67 ± 27.5
|
0.1
|
27.0 ± 1.7
|
0.21 ± 0.02
|
|
Ad-ΔB
|
190 ± 36.4
|
52 ± 17.8
|
0.1
|
29.3 ± 5.5
|
0.20 ± 0.01
|
|
Ad-ΔB/TRAIL + Ad-ΔB/IL-12
|
118 ± 12.5
|
52 ± 42.2
|
0.2
|
30.6. ± 2.1
|
0.21 ± 0.02
|
- HCC-bearing mice were systemically treated with PBS, controlled non-armed Ad-ΔB, or combination of Ad-ΔB/TRAIL+Ad-ΔB/IL-12; at a dosage regimen of 1 × 1010 VP/intravenous injection; three times every other day. 72 h after the last dose, serum levels of hepato-renal function biomarkers of each group were assessed. Data are represented as mean ± SE
